Karakaş, 336 patient colchicine late treatment study: 13% lower mortality [p=0.72], 16% lower ICU admission [p=0.5], and 25% shorter hospitalization [p=0.0001] https://c19p.org/karakas
copied to clipboard
Reducing length of hospital stay with colchicine
et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924
Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with higher dosage (1mg/day vs 0.5mg/day). More control patients were on oxygen at baseline (65% vs. 54%).
|
risk of death, 12.7% lower, RR 0.87, p = 0.72, treatment 16 of 165 (9.7%), control 19 of 171 (11.1%), NNT 71.
|
|
risk of ICU admission, 16.0% lower, RR 0.84, p = 0.50, treatment 30 of 165 (18.2%), control 37 of 171 (21.6%), NNT 29.
|
|
hospitalization time, 25.0% lower, relative time 0.75, p < 0.001, treatment 165, control 171.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
excessive unadjusted differences between groups.
Karakaş et al., 1/31/2022, retrospective, Turkey, Europe, peer-reviewed, 11 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.